12 hrs ago
Morningstar Assigns "AA-" Credit Rating to AstraZeneca plc
AstraZeneca plc has received an "AA-" credit rating from analysts at Morningstar .
Fri Aug 29, 2014
Why AstraZeneca (AZN) Stock Is Higher Today
Must Read: 50 Stocks Hedge Funds Love STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months.
Thu Aug 28, 2014
AbbVie: Growth Story Or Patent Expiration Nightmare?
AbbVie is a global biopharmaceutical company, with over 25,000 employees and products sold in over 170 countries.
Tue Aug 26, 2014
AstraZeneca plc Receives Average Recommendation of "Hold" from Analysts
Shares of AstraZeneca plc have been given an average rating of "Hold" by the twenty-two ratings firms that are currently covering the stock, Stock Ratings News reports .
Sat Aug 23, 2014
Competition And Momentum Weighing On Clovis Oncology
Analysts and investors have started fretting that AstraZeneca's drug will be a stronger potential rival to Clovis's lead drug rociletinib.
Fri Aug 22, 2014
Panmure Gordon Reiterates Hold Rating for AstraZeneca plc
AstraZeneca plc traded down 0.19% during mid-day trading on Friday, hitting $73.05.
Thu Aug 21, 2014
Nektar Therapeutics Has More To Give
Investors should know within a month whether the FDA will approve Movantik, Nektar's opioid-induced constipation drug partnered with AstraZeneca that has $1B+ potential.
Pfizer Inc. Eyes Possible Actavis Bid Whilst Weighing Next Steps Over AstraZeneca PLC
Pfizer Inc. isn't giving up on striking an overseas takeover to cut its tax rate and gain a new pipeline of drugs, even as the potential cost of acquiring AstraZeneca Plc rises.
Why AstraZeneca (AZN) Stock Is Higher Today
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
AstraZeneca plc Receives "Hold" Rating from Beaufort Securities
AstraZeneca plc opened at 4375.50 on Thursday. AstraZeneca plc has a 52 week low of GBX 3086.50 and a 52 week high of GBX 5750.00.
Customer Interaction Solutions
Illumina Announces Strategic Partnerships with AstraZeneca, Janssen...
The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine.
Wed Aug 20, 2014
AstraZeneca PLC, Mitsubishi Tanabe Pharma Corporation Link Up For Diabetes Research
AstraZeneca and Mitsubishi Tanabe Pharma said on Wednesday they said signed a three-year research collaboration into diabetic nephropathy, or kidney failure due to diabetes.
Tue Aug 19, 2014
The Zacks Analyst Blog Highlights: Tesla Motors, CarMax, O'Reilly...
Information contained on this page is provided by an independent third-party content provider.
How Will AstraZeneca (AZN) Stock Respond To U.S. Clearing Heart Drug Trial?
The company said the government was closing its investigation into the 18,000-patient study and no further action was planned.
Mon Aug 18, 2014
Recent Analysts' Ratings Updates for AstraZeneca plc
A number of stock research firms have changed their ratings and price targets for AstraZeneca plc during the last seven days: AstraZeneca plc had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co..
Sun Aug 17, 2014
2nd Half Of 2014 Biotechnology Catalysts--Part 4
Through knowing when PDUFA decisions are going to be made, investors can benefit from the increased momentum and share price heading into the decision.
Thu Aug 14, 2014
Why GlaxoSmithKline Is A Tempting Buy
By now, most investors know all the problems facing pharmaceutical giant GlaxoSmithKline .
Wed Aug 13, 2014
Wall Street Journal
AstraZeneca Gets Good Results From Gout Drug Trials
AstraZeneca PLC reported on Wednesday positive results from three combination Phase III clinical trials of treatments for patients with gout, an inflammatory arthritis.
Fri Aug 08, 2014
Recent Investment Analysts' Ratings Updates for AstraZeneca plc
A number of stock research firms have changed their ratings and price targets for AstraZeneca plc during the last seven days: AstraZeneca plc had its "hold" rating reaffirmed by analysts at Jefferies Group.
Thu Aug 07, 2014
Nektar Therapeutics Harnesses The Power Of AstraZeneca To Move Movantik
Nektar, and Nektar shareholder excitement surrounding FDA approval of Movantik on the fast-approaching date of September 16th might only be exceeded by that of partner AstraZeneca.